Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
Funding Amount
Not stated
Deadline
October 25, 2027
364 days left
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Tribal organizations
- Public colleges & universities
- Tribal governments
- Small businesses
- For-profit businesses
- Special district governments
- Nonprofits (501(c)(3))
- Private colleges & universities
Other requirements
- Territory or Possession.
Overview
The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: PAR-25-104
- Instrument: grant
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Focus Areas & Funding Uses
Fields of Work
- Cancer
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
October 30, 2026
GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)
National Institutes of Health
Amount
$2,000,000 total
Deadline
October 30, 2026
GREGoRi Innovation Projects (U01 Clinical Trial Optional)
National Institutes of Health
Amount
$3 – $500K
Deadline
October 30, 2026
GREGoRi Technology Integration Center (U01, Clinical Trials Optional)
National Institutes of Health
Amount
$3,000,000 total
Deadline
October 30, 2026
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
November 2, 2026
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
November 2, 2026
Ready to apply for Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional). Now let's win it.